logo

NIVF

NewGenIVF Group·NASDAQ
--
--(--)
--
--(--)
6.10 / 10
Outperform

NewGenIVF Group demonstrates satisfactory fundamentals with strengths in PB-ROE, Asset-MV, and Cash-MV factors, contributing to an overall fundamental score of 6.1/10. However, risks are present in Revenue-MV and Gross Profit Margin, which may cap near-term growth. Historical back-tests show positive one-month returns for most factors, supporting a favorable investment view despite these weaknesses.

Fundamental(6.1)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.54
Score1/3
Weight6.72%
1M Return5.63%
Inventory turnover ratio
Value34.21
Score3/3
Weight6.16%
1M Return5.89%
Gross profit margin (%)
Value13.08
Score1/3
Weight0.19%
1M Return0.22%
Profit-MV
Value4.20
Score3/3
Weight24.60%
1M Return13.93%
Net income-Revenue
Value3.87
Score3/3
Weight19.34%
1M Return11.87%
PB-ROE
Value-0.82
Score2/3
Weight13.75%
1M Return11.23%
Current assets turnover ratio
Value0.76
Score1/3
Weight0.26%
1M Return0.27%
Fixed assets turnover ratio
Value10.96
Score2/3
Weight0.03%
1M Return0.03%
Asset-MV
Value-0.51
Score3/3
Weight19.62%
1M Return14.63%
Cash-MV
Value-0.07
Score2/3
Weight9.33%
1M Return7.78%
Is NIVF undervalued or overvalued?
  • NIVF scores 6.10/10 on fundamentals and holds a Discounted valuation at present. Backed by its 128.76% ROE, 380.07% net margin, 0.06 P/E ratio, 0.03 P/B ratio, and 1302.01% earnings growth, these metrics solidify its Outperform investment rating.